What we're reading, April 18, 2016: medical experts ask the Joint Commission to revisit its standards of pain management; study determines low-cost generics just as effective at treating hepatitis C as brand name drugs; and UnitedHealth also pulling out of Michigan Obamacare exchange.
Nonprofit groups and medical experts have asked the Joint Commission to revisit its standards of pain management. According to AP, these critics of how prescription painkillers are administered in the US want health officials to phase out the current hospital procedures and questionnaires used to manage pain. The letter states that current standards foster “dangerous pain control practices” and inadvertently encourages the overprescribing of addictive drugs that have fueled the epidemic of overdoses in the US.
Last week, UnitedHealth announced that it would pull out of the Affordable Care Act (ACA) exchanges in Arkansas and Georgia, and now it has added a third state. In 2017, UnitedHealth will no longer offer plans on the ACA exchange in Michigan, according to The Wall Street Journal. The company expects to lose more than $500 million on its exchange business in 2016, and analysts expected UnitedHealth to pull out of most, if not all, of the 34 states in which it offered plans in 2016.
A new study has determined that low-cost generic drugs are just as safe and effective for treating hepatitis C as the expensive brand name versions. The brand name drugs cost as much as $94,000 a patient, while the generic versions cost less than 1% of that, reported HealthDay. The researchers added that a full course could cost as little as $200 in the coming years.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen